Marcel Romey
9 Papers
Marcel Romey is an academic researcher. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 2, co-authored 4 publications.
Chat about Author
Papers
Homologous recombination deficiency (HRD) as an ovarian cancer biomarker in a real-world cohort - validation of decentralized genomic profiling.
Carsten Denkert,Marcel Romey,Bradley D. Swedlund,Akira Hattesohl,Julia Teply-Szymanski,Stefan Kommoss,Kristine A. Kaiser,Annette Staebler,Andreas du Bois,Albert Grass,Christiane Knappmeyer,Florian Heitz,Cara Solimeno,T Ebel,Philipp Harter,Frederik Marmé,Paul Jank,Timo Gaiser,Chris Neff,Uwe Wagner,Kirsten Timms,Fiona R. Rodepeter +21 more
TL;DR: In this article , the authors evaluated homologous recombination deficiency (HRD) in 514 ovarian carcinoma samples by next-generation sequencing of DNA libraries, including BRCA1/BRCA2 and 26,523 single nucleotide polymorphisms using the standardized Myriad HRD assay, with the predefined cut point of ≥42 for a positive genomic instability score (GIS).
22
Combined Focused Next-Generation Sequencing Assays to Guide Precision Oncology in Solid Tumors: A Retrospective Analysis from an Institutional Molecular Tumor Board
Thomas Tarawneh,Fiona R. Rodepeter,Julia Teply-Szymanski,P. Ross,Vera Koch,Clemens Thölken,Jonas A. Schäfer,Niklas Gremke,Hildegard I.D. Mack,Judith Gold,Jorge Riera-Knorrenschild,Christian Wilhelm,Anja Rinke,Martin Middeke,Andreas Klemmer,Marcel Romey,Akira Hattesohl,Moritz Jesinghaus,Christian Görg,Jens Figiel,Ho-Ryun Chung,Thomas Wündisch,Andreas Neubauer,Carsten Denkert,Elisabeth Mack +24 more
TL;DR: The combined focused sequencing assays detected targetable alterations in the majority of patients and was able to suggest personalized treatments to 75% of the patients, indicating that a combination of focused genetic diagnostics is highly informative for routine cancer care.
Prevalence of Homologous Recombination Deficiency Among Patients With Germline RAD51C/D Breast or Ovarian Cancer
Sara Torres-Esquius,Alba Llop-Guevara,Sara Gutiérrez-Enríquez,Marcel Romey,Alex Teulé,Gemma Llort,Ana Herrero,Pilar Sánchez-Henarejos,Anna Vallmajó,Santiago González-Santiago,Isabel Chirivella,Juana Maria Cano,Begoña Graña,Sara Simonetti,Isabela Díaz de Corcuera,Teresa Ramón y Cajal,Judit Sanz,Sara Serrano,Andrea Otero,Cristina Maria Churruca,Ana Beatriz Sánchez-Heras,Sonia Servitja,C. Guillén-Ponce,Joan Brunet,Carsten Denkert,V. Serra,Judith Balmaña +26 more
TL;DR: The prevalence of HRD based on genomic and functional tumor biomarkers in germline RAD51C/D carriers was less than 70%, which highlights the importance of HRD testing to guide therapeutic decision-making for patients with RAD51C/D-associated cancer.
6
Systematic analysis of HRD testing in ovarian cancer - development of recommendations for optimal assay performance.
Marcel Romey,Fiona Rodepeter,Akira Hattesohl,Kristin Kaiser,Julia Teply-Szymanski,Florian Heitz,A. Staebler,Violeta Serra,Albert Grass,Frederik Marmé,Kirsten M. Timms,Philip Harter,Alba Llop-Guevara,Stefan Kommoss,Jelena Boekhoff,Carsten Denkert +15 more
TL;DR: Based on a systematic analysis of tumor cell content and tumor area, patient high-grade serous ovarian cancer samples that display a tumor cell content ≥30% and a tumor area ≥0.5 cm2 are recommended for HRD testing, to allow for optimal chances of a successful analysis and conclusive results.
3
NGS-Guided Precision Oncology in Breast Cancer and Gynecological Tumors—A Retrospective Molecular Tumor Board Analysis
Niklas Gremke,Fiona R. Rodepeter,Julia Teply-Szymanski,Sebastian Griewing,Jelena Boekhoff,Alina Stroh,Thomas Tarawneh,Jorge Riera-Knorrenschild,Christina Balser,Akira Hattesohl,Martin Middeke,P. Ross,Anne Sophie Litmeyer,Marcel Romey,Thorsten Stiewe,Thomas Wündisch,Andreas Neubauer,Carsten Denkert,Uwe Wagner,Elisabeth Mack +19 more
TL;DR: Overall, NGS-guided precision oncology using panel diagnostics demonstrated improved clinical outcomes in a subset of patients with breast and gynecological cancers in a real-world setting.
2